Small artery remodeling in hypertension

Current Hypertension Reports

Volumn 4, Issue 1, 2002, Pages 49-55

  Mulvany, Michael J ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ARTERY; BLOOD PRESSURE; DRUG EFFECT; HISTOLOGY; HUMAN; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; HUMANS; HYPERTENSION; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

EID: 0036484242     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0053-y     Document Type: Article

References (48)

1. Mulvany MJ, Aalkjaer C: Structure and function of small arteries. Physiol Rev 1990, 70:921-961.
2. Christensen KL, Mulvany MJ: Location of resistance arteries. J Vasc Res 2001, 38:1-12.
3. Struijker Boudier HA: Arteriolar and capillary remodelling in hypertension. Drugs 1999, 59:37-40.
4. Rizzoni D, Porteri E, Castellano M., et al.: Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 1998, 31: 335-341.
5. Schiffrin EL, Park JB, Intengan H.D., Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101: 1653-1659.
6. Heagerty AM, Aalkjaer C, Bund S.J., et al.: Small artery structure in hypertension: dual processes of remodelling and growth. Hypertension 1993, 21: 391-397.
7. Price RJ, Skalak TC: Prazosin administration enhances proliferation of arteriolar adventitial fibroblasts. Microvasc Res 1998, 55:138-145.
8. Mulvany MJ: Remodelling of resistance vessels in essential hypertension. In Hypertension. Edited by Oparil S, Weber MA. Philadelphia: WB Saunders; 2000:125-134.
9. Mulvany MJ, Baumbach GL, Aalkjaer C, et al: Vascular remodelling [letter]. Hypertension 1996, 28:505-506.
10. Pasterkamp G, Schoneveld AH, van Wolferen W, et al: The impact of atherosclerotic arterial remodeling on percentage of luminal stenosis varies widely within the arterial system. A postmortem study. Arterioscler Thromb Vasc Biol 1997, 17:3057-3063.
11. Aalkjaer C, Heagerty AM, Petersen K.K., et al.: Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987, 61: 181-186.
12. Izzard AS, Cragoe EJ, Heagerty AM: Intracellular pH in human resistance arteries in essential hypertension. Hypertension 1991, 17:780-786.
13. Schiffrin EL, Deng LY, Larochelle P: Blunted effects of endothe-lin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992, 10: 437-444.
14. Thybo NK, Stephens N, Cooper A., et al.: Effect of antihyper-tensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995, 25:474-481.
15. Short D: The vascular fault in chronic hypertension with particular reference to the role of medial hypertrophy. Lancet 1966, 1:1302-1304.
16. Korsgaard N, Aalkjaer C, Heagerty A.M., et al.: Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993, 22:523-526.
17. Egan BM, Schork N, Panis R., Hinderliter A: Vascular structure enhances regional resistance responses in mild essential hypertension. J Hypertens 1988, 6:41-48.
18. Korner PI, Angus JA: Structural determinants of vascular resistance properties in hypertension. Haemodynamic and model analysis. J Vasc Res 1992, 29:293-312.
19. Rizzoni D, Porteri E, Castellano M., et al.: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996, 28:785-790.
20. Kvist S, Mulvany MJ: Reduced medication and normalization of vascular structure, but continued hypertension in renovascular patients after revascularization. Cardiovasc Res 2001, 52:136-142.
21. Bund SJ, West KP, Heagerty AM: Effects of protection on resistance artery morphology and reactivity in spontaneously hypertensive and Wistar-Kyoto rats. Circ Res 1991, 68:1230-1240.
22. Pourageaud F, De Mey JGR: Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow. Am J Physiol 1997, 273:H1699-H1706.
23. Su EJ, Lombardi DM, Siegal J, Schwartz SM: Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998, 31:1331-1337.
24. Buus CL, Pourageaud F, Fazzi G.E., et al.: Smooth muscle changes during flow-related remodeling of rat mesenteric resistance arteries. Circ Res 2001, 89:180-186.
25. Bakker EN, van Der Meulen ET, Spaan JA, VanBavel E: Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling. Am J Physiol 2001, 278:H1233-H1240.
26. Touyz RM, Schiffrin EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000, 52:639-672.
27. Intengan HD, Schiffrin EL: Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000, 36:312-338.
28. Berk BC: Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001, 81:999-1030.
29. Xi XP, Graf K, Goetze S., et al.: Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:73-82.
30. Touyz RM, He G, Wu X.H., et al.: Src o is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension 2001, 38:56-64.
31. Allen SP, Liang HM, Hill M.A., Prewitt RL: Elevated pressure stimulates protooncogene expression in isolated mesenteric arteries. Am J Physiol 1996, 271:H1517-H1523.
32. Bardy N, Karillon GJ, Merval R, et al: Differential effects of pressure and flow on DNA and protein synthesis and on fibronectin expression by arteries in a novel organ culture system. Circ Res 1995, 77:684-694.
33. Li C, Xu Q: Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal 2000, 12:435-445.
34. Shi Y, Patel S, Niculescu R., et al.: Role of matrix metallopro-teinases and their tissue inhibitors in the regulation of coronary cell migration. Arterioscler Thromb Vasc Biol 1999, 19:1150-1155.
35. Matrougui K, Eskildsen-Helmond YE, Fiebeler A., et al.: Angiotensin II stimulates extracellular signal-regulated kinase activity in intact pressurized rat mesenteric resistance arteries. Hypertension 2000, 36:617-621.
36. Wesselman JP, Dobrian AD, Schriver S.D., Prewitt RL: Src tyrosine kinases and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases mediate pressure-induced c-fos expression in cannulated rat mesenteric small arteries. Hypertension 2001, 37:955-960.
37. Birukov KG, Lehoux S, Birukova A.A., et al.: Increased pressure induces sustained protein kinase C-independent herbimy-cin A-sensitive activation of extracellular signal-related kinase 1/2 in the rabbit aorta in organ culture. Circ Res 1997, 81: 895-903.
38. Bilder G, Wentz T, Leadley R., et al.: Restenosis following angio-plasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation 1999, 99:3292-3299.
39. Saito Y, Berk BC: Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001, 33:3-7.
40. Eskildsen-Helmond YEG, Mulvany MJ: A possible role for the PDGF-beta-receptor in angiotensin II and pressure activation extracellular regulated signal kinase 1/2 in rat mesenteric arteries [abstract]. Hypertension 2001, 38:973.
41. Folkow B: Structural, myogenic, humoral and nervous factors controlling peripheral resistance. In Hypotensive Drugs. Edited by Harington M. London: Pergamon; 1956:163-174.
42. Julius S: The blood pressure seeking properties of the central nervous system. J Hypertens 1988, 6:177-185.
43. Park JB, Schiffrin EL: Effects of antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Rep 2000, 2:280-288.
44. Christensen KL, Mulvany MJ: Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001, 19:1001-1006.
45. Schiffrin EL, Deng LY, Larochelle P: Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in. Hypertension 1994, 23:83-91.
46. Chillon JM, Baumbach GL: Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteri-olar dilatation in hypertensive rats. Hypertension 2001, 37:1388-1393.
47. Strauer BE, Schwartzkopff B: Left ventricular hypertrophy and coronary microcirculation in hypertensive heart disease. Blood Press Suppl 1997, 2:6-12.
48. Krams R, Kofflard MJ, Duncker D.J., et al.: Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998, 97:230-233.